Latest California Healthline Stories
Facebook Live: It’s 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this Facebook Live chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
A Poor Neighborhood In Chicago Looks To Cuba To Fight Infant Mortality
Infant mortality in some of the poorest ZIP codes in the United States rivals that of countries like war-torn Syria. Cuba, meanwhile, does a good job of keeping babies healthy on a tight budget. A team of Cuban health professionals recently spent time in Chicago helping peers there tackle the daunting problem.
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
VA Clears The Air On Talking To Patients Using Pot
Officials want clinicians to discuss how use of medical marijuana could interact with other parts of their care.
Her Sister’s Keeper: Caring For A Sibling With Mental Illness
Few bonds are as tight as those between sisters. But when one has paranoid schizophrenia, the relationship grows complicated.
Half Of Hospitals In Conn., Del. Hit By Medicare’s Safety Penalties
In California, Medicare penalized 30 percent of the hospitals it assessed. Seven states saw a third or more of their hospitals punished under the federal heath law’s campaign against hospital-acquired conditions.
Readers Have Bones To Pick, From Health System Flaws To Covering Marijuana Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
Bonus Tucked Into GOP Tax Bill For Those Aiming To Deduct Medical Expenses
The House sought to eliminate the tax deduction, generally used by people with serious illnesses or those who need long-term care services but it was eventually restored in the final bill — and expanded.